Investment Thesis
PTC Therapeutics demonstrates exceptional revenue growth (114.5% YoY) with strong operational execution, approaching GAAP profitability at -1.0% net margin. However, negative stockholders' equity and negative operating/free cash flow create financial stress that must be resolved before initiating larger positions, despite adequate liquidity runway.
Strengths
- Explosive revenue growth of 114.5% YoY with strong 16.5% operating margin demonstrates strong execution
- Approaching profitability with net loss improvement of 287.9% YoY and only -2.8M loss on 272.6M revenue
- Excellent liquidity with 2.44x current ratio and 834M cash providing 3+ years runway at current burn rate
Risks
- Negative stockholders' equity of -180.5M indicates structural insolvency and accumulated losses not yet recovered
- Negative operating cash flow of -59M despite positive operating income suggests non-cash working capital drain or operational cash generation problems
- Negative free cash flow of -60.2M consuming cash reserves; sustainability dependent on near-term profitability inflection
Key Metrics to Watch
- Operating cash flow inflection - must demonstrate positive OCF despite revenue growth
- Time to GAAP net income profitability - appears imminent within 1-2 quarters
- Stockholders' equity recovery trajectory following profitability achievement
- Free cash flow normalization relative to strong operating margins
- Revenue growth sustainability to ensure path to sustained profitability
Financial Metrics
Revenue
272.6M
Net Income
-2.8M
EPS (Diluted)
$-0.03
Free Cash Flow
-60.2M
Total Assets
2.9B
Cash
834.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
16.5%
Net Margin
-1.0%
ROE
N/A
ROA
-0.1%
FCF Margin
-22.1%
Balance Sheet & Liquidity
Current Ratio
2.44x
Quick Ratio
2.36x
Debt/Equity
N/A
Debt/Assets
106.3%
Interest Coverage
N/A
Long-term Debt
286.0M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-08T08:36:11.301832 |
Data as of: 2026-03-31 |
Powered by Claude AI